Gonadotroph pituitary adenomas;Adenomes hypophysaires gonadotropes

Annales d'Endocrinologie

Volumn 61, Issue 3, 2000, Pages 258-268

  Chanson, Ph ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Gonadotroph adenomas; Gonadotrophins; Non secreting adenomas; Non functioning adenomas; Pituitary; Radiotherapy

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; PROTIRELIN; SOMATOSTATIN DERIVATIVE; DRUG DERIVATIVE; GONADORELIN; LUTEINIZING HORMONE; SOMATOSTATIN;

GONADOTROPIN RELEASE; HUMAN; HYPOPHYSECTOMY; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; IMMUNOCYTOCHEMISTRY; MACROORCHIDISM; OVARY HYPERSTIMULATION; PROVOCATION TEST; REVIEW; ADENOMA; BLOOD; DRUG ANTAGONISM; DRUG POTENTIATION; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; PATHOLOGY; RADIOTHERAPY; SECRETION;

ADENOMA; DOPAMINE AGONISTS; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS, PITUITARY; HUMANS; HYPOPHYSECTOMY; IMMUNOHISTOCHEMISTRY; LUTEINIZING HORMONE; PITUITARY NEOPLASMS; RADIOTHERAPY; SOMATOSTATIN;

EID: 0033822799     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Gonadotropin-releasing hormone receptor mRNA expression by human pituitary tumors in vitro
2. Human pituitary adenomas express endogenous inhibin subunit and follistatin messenger ribonucleic acids
3. Epidemiology of pituitary tumors
4. Pituitary apoplexy after goserelin
5. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas
6. The cytogenesis and pathogenesis of pituitary adenomas
7. Gonadotropin secretion in vitro by human pituitary null cell adenomas and oncocytomas
8. The first 100 transsphenoidally operated pituitary adenomas in a non-specialised centre: Surgical results and tumour-recurrence
9. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker
10. Follicle-stimulating hormone-secreting pituitary adenomas
11. Reduction of follicle-stimulating hormone (FSH) secretion in FSH-producting pituitary adenoma by bromocriptine
12. Dopamine agonists and pituitary tumor shrinkage
13. Hormone production in clinically non functioning pituitary adenomas
14. Management of large pituitary adenomas by transphenoidal surgery
15. Adenomes gonadotropes
16. An audit of selected patients with non-functioning pituitary adenoma treated by transsphenoidal surgery without irradiation
17. Absence of activating mutations in the GnRH receptor gene in human pituitary gonadotroph adenomas
18. Responses of gonadotropin releasing hormone agonist and antagonist administration in patients with gonadotroph cell adenomas
19. Free luteinizing-hormone beta-subunit in normal subjects and patients with pituitary adenomas
20. Pituitary apoplexy caused by GnRH-agonist treatment revealing gonadotroph adenoma
21. Discordant serum alpha-subunit and FSH concentration in a woman with a pituitary tumour
22. A spontaneous and severe hyperstimulation of the ovaries revealing a gonadotroph adenoma
23. Radiotherapy in the treatment of pituitary adenomas
24. Transsphenoidal microsurgery of pituitary macroadenomas with long-term follow-up results
25. Effects of long-term treatment with the gonadotropin-releasing hormone analog nafarelin in patients with non-functioning pituitary adenomas
26. The clinical and endocrine outcome to transphenoidal microsurgery of non secreting pituitary adenomas
27. Identification of gonadotroph adenomas in men with clinically non functioning adenomas by the luteinizing hormone β subunit response to thyrotropin-releasing hormone
28. Recognition of gonadotroph adenomas in women
29. Inhibition of follicle-stimulating hormone secretion from gonadotroph adenomas by repetitive administration of a gonadotropin-releasing hormone antagonist
30. MR of the pituitary gland postsurgery: Serial MR studies following transsphenoidal resection
31. Gonadotroph adenoma in a premenopausal woman secreting follicle-stimulating hormone and causing ovarian hyperstimulation
32. Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas
33. Molecular genetics of pituitary tumours
34. Giant pituitary adenomas: Role of radiotherapy
35. Abnormal response of luteinizing hormone beta subunit to thyrotropin-releasing hormone in patients with non-functionning pituitary adenoma
36. Serum levels of β-subunit of chorionic gonadotropin in patients with pituitary tumors
37. Expression of three somatostatin receptor subtypes in pituitary adenomas: Evidence for preferential SSTR5 expression in the mammosomatotroph lineage
38. Relative sparing of anterior pituitary function in patients with growth hormone-secreting macroadenomas: Comparison with nonfunctioning macroadenomas
39. MR imaging of pituitary macroadenomas before and after transsphenoidal surgery
40. Pituitary magnetic resonance imaging in normal human volunteers: Occult adenomas in the general population
41. Postoperative radiotherapy for clinically nonfunctioning pituitary adenomas
42. The effects of transsphenoidal surgery on endocrine function and visual fields in patients with functionless pituitary tumours
43. Follicle-stimulating hormone secreting pituitary adenomas: Correlation of reduction of adenoma size with reduction of hormonal hypersecretion after transphenoidal surgery
44. The treatment of pituitary chromophobe adenomas
45. Testicular enlargement and elevated serum inhibin concentrations occur in patients with pituitary macroadenomas secreting follicle-stimulating hormone
46. The adenohypophysis
47. Influence of radiotherapy on long-term relapse in clinically non- secreting pituitary adenomas. A retrospective study (1970-1988)
48. Glycoprotein hormone gene expression and hormone production in pituitary adenomas
49. Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary adenomas
50. Luteinizing hormone-secreting pituitary tumor: Biosynthetic characterization and clinical studies
51. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors
52. Gonadotropin release by clinically non functioning and gonadotroph pituitary adenomas in vivo and in vitro: Relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine
53. Inhibin and follicle-stimulating hormone levels in gonadotroph adenomas: Evidence of a positive correlation with tumour volume in men
54. The effects of bromocriptine, thyrotropin-releasing hormone and gonadotropin-releasing hormone on hormone secretion by gonadotropin-secreting pituitary adenomas in vivo and in vitro
55. Is there a real medical treatment for << non-secreting >> pituitary adenoma?
56. Recovery of visual and endocrine function following transsphenoidal surgery of large nonfunctioning pituitary adenomas
57. Secretion of LH, FSH, and PRL shown by cell culture and immunocytochemistry of human functionless pituitary adenomas
58. New technique for quantitation of pituitary adenoma size: Use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist
59. The pituitary << incidentaloma >>
60. Pituitary apoplexy after leuprolide administration for carcinoma of the prostate
61. A comparison between the diagnostic value of gonadotropins, alpha subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha subunit-secreting, and gonadotroph pituitary adenoma
62. Prevalence of alpha-subunit hypersecretion in patients with pituitary tumors: Clinically non functioning and somatotroph adenomas
63. Decreased follistatin gene expression in gonadotroph adenomas
64. Luteinizing hormone- and alpha subunit-secreting pituitary tumor: Positive feedback of oestrogen
65. A gonadotroph adenoma with a high proportion of basic FSH isohormones by chromatofocusing
66. The Luteinizing Hormone-Releasing Hormone (LHH) agonist (D-Trp6-Pro9-NEt-LHRH) increased rather than lowered LH and alpha subunit levels in a patient with an LH-secreting pituitary tumor
67. Gonadotropin-releasing hormone agonist are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas
68. Lack of effect of a gonadotropin-releasing hormone agonist in a patient with prostate cancer and a gonadotroph adenoma
69. Proceedings: Treatment of nonfunctioning chromophobe adenomas of the pituitary
70. Genetic basis of endocrine disease: Pituitary tumor pathogenesis
71. Gonadotroph adenomas
72. Gonadotroph cell adenomas of the pituitary
73. Comparison of hormonal secretory behavior of gonadotroph cell adenomas in vivo and in culture
74. Thyrotropin-releasing hormone provokes abnormal follicle-stimulating hormone (FSH) and luteinizing hormone responses in men who have pituitary adenomas and FSH hypersecretion
75. Hypersecretion of LH and FSH by a pituitary adenoma
76. Pituitary adenomas: Findings of postoperative MR imaging
77. Incidental pituitary lesions in 1,000 unselected autopsy specimens
78. Pituitary adenomas: Current concepts in classification, histopathology, and molecular biology
79. La cellule gonadotrope humaine normale et pathologique
80. The human gonadotropic adenoma: Pathologic diagnosis and hormonal correlations in 26 tumors
81. Ovarian hyperstimulation caused by gonadotroph adenoma secreting follicle-stimulating hormone in 28-year-old woman
82. Follicle-stimulating hormone- and alpha-subunit-secreting pituitary tumor treated with bromocriptine
83. Treatment and recurrences in 135 pituitary adenomas
84. A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas
85. The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas
86. Extensive clinical experience: Surgical management of pituitary tumors
87. Pituitary adenomas: Factors in treatment